A Phase 1/2 Multicenter, Single-Arm, Open-Label, Dose-Escalation Study of Birinapant in Combination With Pembrolizumab (KEYTRUDA) in Patients With Relapsed or Refractory Solid Tumors

Trial Profile

A Phase 1/2 Multicenter, Single-Arm, Open-Label, Dose-Escalation Study of Birinapant in Combination With Pembrolizumab (KEYTRUDA) in Patients With Relapsed or Refractory Solid Tumors

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Aug 2017

At a glance

  • Drugs Birinapant (Primary) ; Pembrolizumab
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors TetraLogic Pharmaceuticals
  • Most Recent Events

    • 18 Aug 2017 According to a Medivir AB media release, first patient has been enrolled.
    • 25 Jul 2017 According to a Medivir AB media release, company expects to initiate the phase I portion of that study in the third quarter 2017.
    • 18 Oct 2016 Planned End Date changed from 1 Mar 2019 to 1 Mar 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top